Literature DB >> 29174841

New hope for hyperlipidemia management: Inclisiran.

Dhrubajyoti Bandyopadhyay1, Adrija Hajra2, Kumar Ashish3, Arshna Qureshi4, Somedeb Ball5.   

Abstract

Entities:  

Keywords:  Hyperlipidemia; Inclisiran; Low-density lipoprotein; PCSK9

Mesh：

Substances：

Year:  2017        PMID： 29174841     DOI： 10.1016/j.jjcc.2017.10.017

Source DB:  PubMed          Journal:  J Cardiol        ISSN： 0914-5087            Impact factor:   3.159


× No keyword cloud information.
  4 in total

Review 1.  Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies.

Authors:  Giovanni Ciccarelli; Saverio D'Elia; Michele De Paulis; Paolo Golino; Giovanni Cimmino
Journal:  Diseases       Date:  2018-03-17

Review 2.  Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia.

Authors:  Constantine E Kosmas; Alba Muñoz Estrella; Andreas Sourlas; Delia Silverio; Elizabeth Hilario; Peter D Montan; Eliscer Guzman
Journal:  Diseases       Date:  2018-07-13

Review 3.  Low-density lipoprotein cholesterol lowering treatment: the current approach.

Authors:  Irina Crismaru; Anca Pantea Stoian; Ovidiu Gabriel Bratu; Mihnea-Alexandru Gaman; Ana Maria Alexandra Stanescu; Nicolae Bacalbasa; Camelia Cristina Diaconu
Journal:  Lipids Health Dis       Date:  2020-05-06       Impact factor: 3.876

Review 4.  Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule.

Authors:  Motasim M Jawi; Jiri Frohlich; Sammy Y Chan
Journal:  J Lipids       Date:  2020-02-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.